Skip to main content
Erschienen in: Diabetologia 9/2009

01.09.2009 | Review

Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?

verfasst von: K. Færch, K. Borch-Johnsen, J. J. Holst, A. Vaag

Erschienen in: Diabetologia | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Prior to the development of type 2 diabetes, glucose levels increase into the prediabetic states of isolated impaired fasting glycaemia (i-IFG), isolated impaired glucose tolerance (i-IGT), or combined IFG/IGT. A better understanding of the aetiology and pathophysiology of the prediabetic states might give a basis for the development of individualised prevention and treatment strategies for type 2 diabetes. Several studies have examined mechanisms and potential aetiological factors leading to the development of the different prediabetic states. The pathophysiology of i-IFG seems to include the following key defects: reduced hepatic insulin sensitivity, stationary beta cell dysfunction and/or chronic low beta cell mass, altered glucagon-like peptide-1 secretion and inappropriately elevated glucagon secretion. Conversely, the prediabetic state i-IGT is characterised by reduced peripheral insulin sensitivity, near-normal hepatic insulin sensitivity, progressive loss of beta cell function, reduced secretion of glucose-dependent insulinotropic polypeptide and inappropriately elevated glucagon secretion. Individuals developing combined IFG/IGT exhibit severe defects in both peripheral and hepatic insulin sensitivity as well as a progressive loss of beta cell function. The aetiologies of i-IFG and i-IGT also seem to differ, with i-IFG being predominantly related to genetic factors, smoking and male sex, while i-IGT is predominantly related to physical inactivity, unhealthy diet and short stature. Since the transition from the prediabetic states to overt type 2 diabetes is characterised by a non-reversible vicious cycle that includes severe deleterious effects on glucose metabolism, there are good reasons to use the well-established aetiological and pathophysiological differences in i-IFG, i-IGT and IFG/IGT to design individualised preventive strategies.
Literatur
2.
Zurück zum Zitat Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef
3.
Zurück zum Zitat Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253–283PubMedCrossRef Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253–283PubMedCrossRef
4.
Zurück zum Zitat Vilsbøll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897–4903PubMedCrossRef Vilsbøll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897–4903PubMedCrossRef
5.
Zurück zum Zitat Golay A, Swislocki AL, Chen YD, Reaven GM (1987) Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692–696PubMedCrossRef Golay A, Swislocki AL, Chen YD, Reaven GM (1987) Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692–696PubMedCrossRef
6.
Zurück zum Zitat Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J (1995) Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 96:2528–2533PubMedCrossRef Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J (1995) Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 96:2528–2533PubMedCrossRef
7.
Zurück zum Zitat Rasouli N, Kern P (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93(11 Suppl 1):s64–s73PubMedCrossRef Rasouli N, Kern P (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93(11 Suppl 1):s64–s73PubMedCrossRef
8.
Zurück zum Zitat Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD (2001) Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 280:E1000–E1006PubMed Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD (2001) Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 280:E1000–E1006PubMed
9.
Zurück zum Zitat Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376–1382PubMedCrossRef Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376–1382PubMedCrossRef
10.
Zurück zum Zitat DeFronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795PubMedCrossRef DeFronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795PubMedCrossRef
11.
Zurück zum Zitat O’Rahilly S, Hattersley A, Vaag A, Gray H (1994) Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet 344:585–589PubMedCrossRef O’Rahilly S, Hattersley A, Vaag A, Gray H (1994) Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet 344:585–589PubMedCrossRef
12.
13.
Zurück zum Zitat Færch K, Vaag A, Holst J, Glümer C, Pedersen O, Borch-Johnsen K (2008) Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51:853–861PubMedCrossRef Færch K, Vaag A, Holst J, Glümer C, Pedersen O, Borch-Johnsen K (2008) Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51:853–861PubMedCrossRef
14.
Zurück zum Zitat Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance—results from the veterans administration genetic epidemiology study. Diabetes 55:1430–1435PubMedCrossRef Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance—results from the veterans administration genetic epidemiology study. Diabetes 55:1430–1435PubMedCrossRef
15.
Zurück zum Zitat Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203PubMedCrossRef Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203PubMedCrossRef
16.
Zurück zum Zitat Meyer C, Szoke E, Pimenta W et al (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914PubMedCrossRef Meyer C, Szoke E, Pimenta W et al (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914PubMedCrossRef
17.
Zurück zum Zitat Tripathy D, Almgren P, Tuomi T, Groop L (2004) Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 27:2204–2210PubMedCrossRef Tripathy D, Almgren P, Tuomi T, Groop L (2004) Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 27:2204–2210PubMedCrossRef
18.
Zurück zum Zitat Wasada T, Kuroki H, Katsumori K et al (2004) Who are more insulin resistant, people with IFG or people with IGT? Diabetologia 47:759–760CrossRef Wasada T, Kuroki H, Katsumori K et al (2004) Who are more insulin resistant, people with IFG or people with IGT? Diabetologia 47:759–760CrossRef
19.
Zurück zum Zitat Færch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K (2009) Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance—the Inter99 study. Diabetes Care 32:439–444PubMedCrossRef Færch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K (2009) Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance—the Inter99 study. Diabetes Care 32:439–444PubMedCrossRef
20.
Zurück zum Zitat Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I (2006) Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 22:126–130PubMedCrossRef Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I (2006) Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 22:126–130PubMedCrossRef
21.
Zurück zum Zitat Novoa FJ, Boronat M (2005) Saavedra P et al Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: The Telde study. Diabetes Care 28:2388–2393PubMedCrossRef Novoa FJ, Boronat M (2005) Saavedra P et al Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: The Telde study. Diabetes Care 28:2388–2393PubMedCrossRef
22.
Zurück zum Zitat DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
23.
Zurück zum Zitat Man CD, Toffolo G, Basu R, Rizza RA, Cobelli C (2008) Use of labeled oral minimal model to measure hepatic insulin sensitivity. Am J Physiol Endocrinol Metab 295:E1152–E1159PubMedCrossRef Man CD, Toffolo G, Basu R, Rizza RA, Cobelli C (2008) Use of labeled oral minimal model to measure hepatic insulin sensitivity. Am J Physiol Endocrinol Metab 295:E1152–E1159PubMedCrossRef
24.
Zurück zum Zitat Vaag A, Alford F, Henriksen FL, Christopher M, Beck-Nielsen H (1995) Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 38:326–336PubMedCrossRef Vaag A, Alford F, Henriksen FL, Christopher M, Beck-Nielsen H (1995) Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 38:326–336PubMedCrossRef
25.
Zurück zum Zitat Bock G, Chittilapilly E, Basu R et al (2007) Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703–1711PubMedCrossRef Bock G, Chittilapilly E, Basu R et al (2007) Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703–1711PubMedCrossRef
26.
Zurück zum Zitat Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
27.
Zurück zum Zitat Qiao Q (2005) Are insulin resistance, impaired fasting glucose and impaired glucose tolerance all equally strongly related to age? Diabet Med 22:1476–1481PubMedCrossRef Qiao Q (2005) Are insulin resistance, impaired fasting glucose and impaired glucose tolerance all equally strongly related to age? Diabet Med 22:1476–1481PubMedCrossRef
28.
Zurück zum Zitat Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMedCrossRef Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMedCrossRef
29.
Zurück zum Zitat Chang-Chen K, Mullur R, Bernal-Mizrachi E (2008) Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 9:329–343PubMedCrossRef Chang-Chen K, Mullur R, Bernal-Mizrachi E (2008) Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 9:329–343PubMedCrossRef
30.
Zurück zum Zitat Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM (2006) The natural course of beta cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114–1120PubMedCrossRef Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM (2006) The natural course of beta cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114–1120PubMedCrossRef
31.
Zurück zum Zitat Ahrén B, Pacini G (1997) Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 273:E701–E707PubMed Ahrén B, Pacini G (1997) Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 273:E701–E707PubMed
32.
Zurück zum Zitat Laakso M, Zilinskaite J, Hansen T et al (2008) Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51:502–511PubMedCrossRef Laakso M, Zilinskaite J, Hansen T et al (2008) Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51:502–511PubMedCrossRef
33.
Zurück zum Zitat Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRef Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRef
34.
Zurück zum Zitat Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998–2003PubMedCrossRef Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998–2003PubMedCrossRef
35.
Zurück zum Zitat Abdul-Ghani MA, DeFronzo RA (2007) Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab 92:1778–1784PubMedCrossRef Abdul-Ghani MA, DeFronzo RA (2007) Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab 92:1778–1784PubMedCrossRef
36.
Zurück zum Zitat Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29PubMed Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29PubMed
37.
Zurück zum Zitat Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M (2005) Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54:1168–1173PubMedCrossRef Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M (2005) Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54:1168–1173PubMedCrossRef
38.
Zurück zum Zitat Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852–858PubMedCrossRef Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852–858PubMedCrossRef
39.
Zurück zum Zitat Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef
40.
Zurück zum Zitat Ahrén B, Larsson H, Holst JJ (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127–131PubMedCrossRef Ahrén B, Larsson H, Holst JJ (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127–131PubMedCrossRef
41.
Zurück zum Zitat Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723PubMedCrossRef Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723PubMedCrossRef
42.
Zurück zum Zitat Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687PubMedCrossRef Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687PubMedCrossRef
43.
Zurück zum Zitat Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, DeFronzo R (2008) Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 45:147–150PubMedCrossRef Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, DeFronzo R (2008) Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 45:147–150PubMedCrossRef
44.
Zurück zum Zitat Balkau B, Mhamdi L, Oppert JM et al (2008) Physical activity and insulin sensitivity: the RISC Study. Diabetes 57:2613–2618PubMedCrossRef Balkau B, Mhamdi L, Oppert JM et al (2008) Physical activity and insulin sensitivity: the RISC Study. Diabetes 57:2613–2618PubMedCrossRef
45.
Zurück zum Zitat Assah FK, Brage S, Ekelund U, Wareham NJ (2008) The association of intensity and overall level of physical activity energy expenditure with a marker of insulin resistance. Diabetologia 51:1399–1407PubMedCrossRef Assah FK, Brage S, Ekelund U, Wareham NJ (2008) The association of intensity and overall level of physical activity energy expenditure with a marker of insulin resistance. Diabetologia 51:1399–1407PubMedCrossRef
46.
Zurück zum Zitat Færch K, Vaag A, Witte DR, Jørgensen T, Pedersen O, Borch-Johnsen K (2009) Predictors of future fasting and 2-hour post-OGTT plasma glucose levels in middle-aged men and women—the Inter99 study. Diabet Med 26:377–383PubMedCrossRef Færch K, Vaag A, Witte DR, Jørgensen T, Pedersen O, Borch-Johnsen K (2009) Predictors of future fasting and 2-hour post-OGTT plasma glucose levels in middle-aged men and women—the Inter99 study. Diabet Med 26:377–383PubMedCrossRef
47.
Zurück zum Zitat Healy GN, Dunstan DW, Shaw JE, Zimmet PZ, Owen N (2006) Beneficial associations of physical activity with 2-h but not fasting blood glucose in Australian adults. Diabetes Care 29:2598–2604PubMedCrossRef Healy GN, Dunstan DW, Shaw JE, Zimmet PZ, Owen N (2006) Beneficial associations of physical activity with 2-h but not fasting blood glucose in Australian adults. Diabetes Care 29:2598–2604PubMedCrossRef
48.
Zurück zum Zitat Assah FK, Ekelund U, Brage S, Mbanya JC, Wareham NJ (2009) free-living physical activity energy expenditure is strongly related to glucose intolerance in Cameroonian adults independently of obesity. Diabetes Care 32:367–369PubMedCrossRef Assah FK, Ekelund U, Brage S, Mbanya JC, Wareham NJ (2009) free-living physical activity energy expenditure is strongly related to glucose intolerance in Cameroonian adults independently of obesity. Diabetes Care 32:367–369PubMedCrossRef
49.
Zurück zum Zitat Feskens EJ, Virtanen SM, Räsänen L et al (1995) Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 18:1104–1112PubMedCrossRef Feskens EJ, Virtanen SM, Räsänen L et al (1995) Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 18:1104–1112PubMedCrossRef
50.
Zurück zum Zitat Van Dam RM, Stampfer M, Willett WC, Hu FB, Rimm EB (2002) Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25:417–424PubMedCrossRef Van Dam RM, Stampfer M, Willett WC, Hu FB, Rimm EB (2002) Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25:417–424PubMedCrossRef
51.
Zurück zum Zitat Pereira MA, Jacobs DR, Pins JJ et al (2002) Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr 75:848–855PubMed Pereira MA, Jacobs DR, Pins JJ et al (2002) Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr 75:848–855PubMed
52.
Zurück zum Zitat Lau C, Glümer C, Toft U et al (2008) Identification and reproducibility of dietary patterns in a Danish cohort: the Inter99 study. Br J Nutr 99:1089–1098PubMedCrossRef Lau C, Glümer C, Toft U et al (2008) Identification and reproducibility of dietary patterns in a Danish cohort: the Inter99 study. Br J Nutr 99:1089–1098PubMedCrossRef
53.
Zurück zum Zitat Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T (2006) The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 study. Eur J Clin Nutr 61:270–278PubMedCrossRef Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T (2006) The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 study. Eur J Clin Nutr 61:270–278PubMedCrossRef
54.
Zurück zum Zitat Lau C, Toft U, Tetens I et al (2009) Dietary patterns predict changes in two-hour post-oral glucose tolerance test plasma glucose concentrations in middle-aged adults. J Nutr 139:588–593PubMedCrossRef Lau C, Toft U, Tetens I et al (2009) Dietary patterns predict changes in two-hour post-oral glucose tolerance test plasma glucose concentrations in middle-aged adults. J Nutr 139:588–593PubMedCrossRef
55.
Zurück zum Zitat Mooy JM, Grootenhuis PA, de Vries H et al (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273PubMedCrossRef Mooy JM, Grootenhuis PA, de Vries H et al (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273PubMedCrossRef
56.
Zurück zum Zitat Smith U (1994) Carbohydrates, fat, and insulin action. Am J Clin Nutr 59(Suppl 3):686S–689SPubMed Smith U (1994) Carbohydrates, fat, and insulin action. Am J Clin Nutr 59(Suppl 3):686S–689SPubMed
57.
Zurück zum Zitat Feskens EJM, Kromhout D (1989) Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men. The Zutphen Study. Am J Epidemiol 130:1101–1108PubMed Feskens EJM, Kromhout D (1989) Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men. The Zutphen Study. Am J Epidemiol 130:1101–1108PubMed
58.
Zurück zum Zitat Bamia C, Trichopoulou A, Lenas D, Trichopoulos D (2004) Tobacco smoking in relation to body fat mass and distribution in a general population sample. Int J Obes Relat Metab Disord 28:1091–1096PubMedCrossRef Bamia C, Trichopoulou A, Lenas D, Trichopoulos D (2004) Tobacco smoking in relation to body fat mass and distribution in a general population sample. Int J Obes Relat Metab Disord 28:1091–1096PubMedCrossRef
59.
Zurück zum Zitat Song F, Jia W, Yao Y et al (2007) Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type 2 diabetes. Clin Sci 112:599–606PubMedCrossRef Song F, Jia W, Yao Y et al (2007) Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type 2 diabetes. Clin Sci 112:599–606PubMedCrossRef
60.
Zurück zum Zitat Kong C, Nimmo L, Elatrozy T et al (2001) Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis 156:373–378PubMedCrossRef Kong C, Nimmo L, Elatrozy T et al (2001) Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis 156:373–378PubMedCrossRef
61.
Zurück zum Zitat Lyssenko V (2008) The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Curr Opin Clin Nutr Metab Care 11:385–392PubMedCrossRef Lyssenko V (2008) The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Curr Opin Clin Nutr Metab Care 11:385–392PubMedCrossRef
62.
Zurück zum Zitat Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
63.
Zurück zum Zitat Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 93:4013–4019PubMedCrossRef Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 93:4013–4019PubMedCrossRef
64.
Zurück zum Zitat Sparsø T, Bonnefond A, Andersson E et al (2009) G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release. Diabetes 58:1450–1456PubMedCrossRef Sparsø T, Bonnefond A, Andersson E et al (2009) G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release. Diabetes 58:1450–1456PubMedCrossRef
65.
Zurück zum Zitat Lyssenko V, Nagorny CLF, Erdos MR et al (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRef Lyssenko V, Nagorny CLF, Erdos MR et al (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRef
66.
Zurück zum Zitat Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C et al (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89–94PubMedCrossRef Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C et al (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89–94PubMedCrossRef
67.
Zurück zum Zitat Rose CS, Ek J, Urhammer SA et al (2005) A –30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 54:3026–3031PubMedCrossRef Rose CS, Ek J, Urhammer SA et al (2005) A –30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 54:3026–3031PubMedCrossRef
68.
Zurück zum Zitat Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S et al (2006) A common haplotype of the glucokinase gene alters fasting glucose and birth weight: Association in six studies and population-genetics analyses. Am J Hum Genet 79:991–1001PubMedCrossRef Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S et al (2006) A common haplotype of the glucokinase gene alters fasting glucose and birth weight: Association in six studies and population-genetics analyses. Am J Hum Genet 79:991–1001PubMedCrossRef
69.
Zurück zum Zitat Sparsø T, Andersen G, Nielsen T, Burgdorf K, Gjesing A, Nielsen A et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75PubMedCrossRef Sparsø T, Andersen G, Nielsen T, Burgdorf K, Gjesing A, Nielsen A et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75PubMedCrossRef
70.
Zurück zum Zitat Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121PubMedCrossRef Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121PubMedCrossRef
71.
Zurück zum Zitat Bouatia-Naji N, Rocheleau G, Van-Lommel L et al (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320:1085–1088PubMedCrossRef Bouatia-Naji N, Rocheleau G, Van-Lommel L et al (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320:1085–1088PubMedCrossRef
72.
Zurück zum Zitat Chen WM, Erdos MR, Jackson AU et al (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620–2628PubMed Chen WM, Erdos MR, Jackson AU et al (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620–2628PubMed
73.
Zurück zum Zitat Hu C, Zhang R, Wang C et al (2009) A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia 52:451–456PubMedCrossRef Hu C, Zhang R, Wang C et al (2009) A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia 52:451–456PubMedCrossRef
74.
Zurück zum Zitat Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101PubMedCrossRef Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101PubMedCrossRef
75.
Zurück zum Zitat Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma 2 (PPAR-gamma 2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176PubMedCrossRef Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma 2 (PPAR-gamma 2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176PubMedCrossRef
76.
Zurück zum Zitat Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef
77.
Zurück zum Zitat Grunnet LG, Brons C, Jacobsen S et al (2009) Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609. J Clin Endocrinol Metab 94:596–602PubMedCrossRef Grunnet LG, Brons C, Jacobsen S et al (2009) Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609. J Clin Endocrinol Metab 94:596–602PubMedCrossRef
78.
Zurück zum Zitat Sparsø T, Grarup N, Andreasen C et al (2009) Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia 52:1308–1314PubMedCrossRef Sparsø T, Grarup N, Andreasen C et al (2009) Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia 52:1308–1314PubMedCrossRef
79.
Zurück zum Zitat Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE (2008) Differences in height explain gender differences in the response to the oral glucose tolerance test—the AusDiab study. Diabet Med 25:296–302PubMedCrossRef Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE (2008) Differences in height explain gender differences in the response to the oral glucose tolerance test—the AusDiab study. Diabet Med 25:296–302PubMedCrossRef
80.
Zurück zum Zitat Leger J, Levy-Marchal C, Bloch J et al (1997) Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 315:341–347PubMed Leger J, Levy-Marchal C, Bloch J et al (1997) Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 315:341–347PubMed
81.
Zurück zum Zitat Ravelli ACJ, van der Meulen JHP, Michels RPJ et al (1998) Glucose tolerance in adults after prenatal exposure to famine. Lancet 351:173–177PubMedCrossRef Ravelli ACJ, van der Meulen JHP, Michels RPJ et al (1998) Glucose tolerance in adults after prenatal exposure to famine. Lancet 351:173–177PubMedCrossRef
82.
Zurück zum Zitat Hales CN, Barker DJ, Clark PM et al (1991) Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303:1019–1022PubMedCrossRef Hales CN, Barker DJ, Clark PM et al (1991) Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303:1019–1022PubMedCrossRef
83.
Zurück zum Zitat Poulsen P, Vaag AA, Kyvik KO, Møller-Jensen D, Beck-Nielsen H (1997) Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia 40:439–446PubMedCrossRef Poulsen P, Vaag AA, Kyvik KO, Møller-Jensen D, Beck-Nielsen H (1997) Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia 40:439–446PubMedCrossRef
84.
Zurück zum Zitat Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA (2002) Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. Diabetes 51:1271–1280PubMedCrossRef Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA (2002) Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. Diabetes 51:1271–1280PubMedCrossRef
85.
Zurück zum Zitat Brøns C, Jensen CB, Storgaard H et al (2008) Mitochondrial function in skeletal muscle is normal and unrelated to insulin action in young men born with low birth weight. J Clin Endocrinol Metab 93:3885–3892PubMedCrossRef Brøns C, Jensen CB, Storgaard H et al (2008) Mitochondrial function in skeletal muscle is normal and unrelated to insulin action in young men born with low birth weight. J Clin Endocrinol Metab 93:3885–3892PubMedCrossRef
86.
Zurück zum Zitat Glümer C, Jørgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef Glümer C, Jørgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef
87.
Zurück zum Zitat Dunstan DW, Zimmet PZ, Welborn TA et al (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829–834PubMedCrossRef Dunstan DW, Zimmet PZ, Welborn TA et al (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829–834PubMedCrossRef
88.
Zurück zum Zitat Williams JW, Zimmet PZ, Shaw JE et al (2003) Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med 20:915–920PubMedCrossRef Williams JW, Zimmet PZ, Shaw JE et al (2003) Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med 20:915–920PubMedCrossRef
89.
Zurück zum Zitat Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMedCrossRef Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMedCrossRef
90.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
91.
Zurück zum Zitat Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
92.
Zurück zum Zitat Bloomgarden ZT (2008) American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three. Diabetes Care 31:2404–2409PubMedCrossRef Bloomgarden ZT (2008) American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three. Diabetes Care 31:2404–2409PubMedCrossRef
93.
94.
Zurück zum Zitat The International Expert Committee (2009) International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care doi:10.2337/dc09-9033 The International Expert Committee (2009) International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care doi:10.​2337/​dc09-9033
95.
Zurück zum Zitat Mooy JM, Grootenhuis PA, de Vries H et al (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298–305PubMedCrossRef Mooy JM, Grootenhuis PA, de Vries H et al (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298–305PubMedCrossRef
Metadaten
Titel
Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?
verfasst von
K. Færch
K. Borch-Johnsen
J. J. Holst
A. Vaag
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 9/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1443-3

Weitere Artikel der Ausgabe 9/2009

Diabetologia 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.